Versant's plans

Versant Ventures says it will not alter its plans to invest evenly between therapeutics and medical device companies, even though it is left with only two active therapeutics-focused managing directors - Samuel Colella and Bradley Bolzon - after four of the firm's 13 managing directors decided they would not make new investments from the firm's next fund.

"The changes were in preparation for raising the next fund, which is imminent," said Managing Director Brian Atwood, who is part of the group who will not be actively investing in the next fund...